Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
IDEXX Laboratories director Joseph L. Hooley acquired 43 deferred stock units tied to the company’s common stock as a compensation award. The units were valued using a reference price of $560.80 per share, reflecting the conversion of $24,375.00 of cash compensation he chose to defer.
Each deferred stock unit represents the right to receive one IDEXX share in the future. The units vest immediately and will be settled in stock after Hooley leaves the Board or on another fixed date allowed under the director plan. Following this grant, he directly holds 118 deferred stock units.
IDEXX Laboratories Inc reported that Vanguard Capital Management beneficially owns 5,976,472 shares of Common Stock, representing 7.51% of the class. The filer reports sole dispositive power over 5,976,472 shares and sole voting power over 793,965 shares. The filing states the ownership reflects securities held by Vanguard affiliates and funds and is signed by Ashley Grim, Head of Global Fund Administration.
IDEXX Laboratories presents its 2026 proxy, highlighting strong 2025 growth, major product launches, an upcoming CEO transition and several governance proposals. Revenue reached $4.3B, up 10%, with operating profit of $1.4B and diluted EPS of $13.08, a 23% increase, supported by margin expansion and resilient demand despite lower U.S. vet visit volumes.
The company underscores innovation such as IDEXX Cancer Dx for early canine cancer detection, the inVue Dx cellular analyzer and the ImageVue DR50 Plus imaging system. Shareholders will vote on director elections, auditor ratification, executive pay, declassifying the Board, a 25% special-meeting right and a separate special-meeting shareholder proposal the Board opposes.
IDEXX Laboratories Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately in reliance on SEC Release No. 34-39538.
IDEXX Laboratories announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will leave her role effective April 13, 2026, then serve as a special advisor on an as‑needed basis until July 13, 2026.
Under a separation agreement, IDEXX will provide salary continuation for 104 weeks totaling $1,230,000 and pay her target annual bonus for two years totaling $984,000, alongside a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for 2025 and 2026 tax or financial planning services.
Unvested stock options, restricted stock units and performance stock units will be forfeited as of the final employment date, while vested stock options remain exercisable under existing award terms. IDEXX characterizes the move as a termination without cause tied to elimination of her position and obtained a broad release, non‑disparagement and ongoing cooperation commitments.
IDEXX Laboratories, Inc. presents its preliminary 2026 Proxy Statement summarizing 2025 performance, corporate priorities and governance matters.
The company reports $4.3B revenue, $13.08 diluted EPS, 10% reported revenue growth and highlights innovation milestones and a planned CEO transition effective upon adjournment of the 2026 Annual Meeting on May 12, 2026.
IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.
The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share. After this sale, Hunt directly held 18,140.944 shares and indirectly held 160 shares jointly with a spouse.
According to a footnote, the weighted average sale price reflects individual trades executed between $634.5301 and $634.8201 per share.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported corrected equity awards and updated holdings. The amended filing states that on February 12, 2026 he received a non‑qualified stock option for 13,667 shares and an incentive stock option for 162 shares, both with an exercise price equal to that day’s closing stock price.
The non‑qualified option vests in four annual installments beginning February 14, 2027, while the incentive stock option becomes exercisable in a single installment on February 14, 2030. The amendment clarifies that previously reported grants of 6,319 restricted stock units did not occur, and notes his common stock holdings include 184 vested but deferred restricted stock units.